AmStem Reports Positive Early Results From SteMixxTM Consumer Study

Main Category: Dermatology
Article Date: 15 Jul 2010 - 18:00 PDT


AmStem Corporation (OTCBB: AMST), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced positive early results from its preliminary consumer study of SteMixx™.

David Stark, President of AmStem International, Inc. said, "During the first few days, we asked participants of our initial consumer study of SteMixx™ for their initial impressions. We were not surprised but certainly pleased at how positively they responded."

Full study results will be available at the end of this month, but participants have already been calling the AmStem International office in San Francisco, with comments such as, "Where can I buy this? This is amazing!" and "I have had good results after just one application." Over 64% of responding participants have made positive comments. The rest said it was too early to tell.

Samples of comments made by participants (reprinted by permission):

- "Much tighter feeling and less puffy after just two uses"
- "Less redness in broken capillaries, better circulation in skin, not as much eye puffiness"
- "Keeps the skin moist. Feels a bit tighter."
- "Sun spots fading"
- "Less hyper pigmentation"
- "Skin softer and complexion more even"
- "Clearer skin, seems less puffy"

One participant added, "So many manufacturers take advantage of people with false claims. Thank you for using real ingredients that our own bodies notice as their own." Twenty-one women are participating in the SteMixx™ consumer study across the country. The study asks its participants to refrain from using any other facial skin care products for one month (except for cleanser and sunscreen). Those with any type of recent facial procedure, such as a light or deep peel, dermabrasions or injections were excluded.

Based on these early positive results, AmStem has engaged a labeling consultant for their flagship SteMixx™ product to make it available for retail consumer use as soon as possible in the U.S.

In a related development, AmStem has finalized its submission to an independent Institutional Review Board (IRB) to begin the first clinical trial of SteMixx in the United States.

Stark said, "This study will provide information to help decide what claims we will make in our labeling and advertising of SteMixx™. The principal investigator will be Dr. Shelly Friedman of the Scottsdale Institute for Cosmetic Dermatology. The study is expected to begin enrollment immediately after IRB approval."

About SteMixx™

SteMixx™, along with an extensive line of cosmeceutical and hair restoration products, was developed by Dr. Han Hoon, CEO of Histostem, Ltd., in Seoul, Korea. Histostem operates one of the largest cord blood banks in the world with over 80,000 units stored for personal and unrelated transplant uses.

SteMixx™ has been approved by the Korean FDA as a "functional cream" for the treatment of facial skin disfiguration associated with signs of aging such as wrinkles. AmStem's professional studies are for the purpose of validating these claims, which have not yet been reviewed by the U.S. FDA.

Source:
AmStem Inc.

• Additional
• References
• Citations